As a leader in muscle biology research, we are dedicated to our mission of improving the lives of people confronting devastating diseases of impaired muscle function.
SOUTH SAN FRANCISCO, Calif. , July 12, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report second quarter results on July 26, 2018 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a...READ MORE ›
The enduring power of our science and the benefits of a diversified pipeline strategy came into focus during the past year. We now press forward with a solid foundation on which we are planning for a prosperous future.
People fighting amyotrophic lateral sclerosis have few treatment options; we are dedicated to changing the progression of this fatal disease.
Heart failure death and disability rates continue to rise, despite current treatment options. With Amgen, we are developing a novel therapy that may improve cardiac performance in people with heart failure.
People suffering from spinal muscular atrophy experience devastating loss of muscle function. With Astellas, we are working on a treatment that may enhance skeletal muscle performance in these and other patients.